Brainstem glioma clinical features and treatment outcomes: a case series
DOI:
https://doi.org/10.18203/issn.2454-2156.IntJSciRep20232472Keywords:
BGs, Radiation, TemozolomideAbstract
A diverse category of gliomas that mostly affect youngsters are known as brainstem gliomas (BGs). The diffuse intrinsic pontine glioma (DIPG), exophytic medullary glioma, and tectal glioma can be divided into categories based on architecture and clinical behaviour. The most frequent BG is DIPG. The median age at start is 6.5 years, and the median survival is less than a year. The fact that adults with DIPG live longer suggests that their tumours are less aggressive and have physiologically distinct origins than those in children. Patients may appear with one or more of the following symptoms: ataxia, long tract signs, or malfunction of the cranial nerves. The majority of the pons is occupied by an infiltrative lesion on magnetic resonance imaging, and contrast enhancement is typically not noticeable. Fractionated radiation is the norm in medicine.
Metrics
References
Salmaggi A, Fariselli L, Milanesi I. Natural history and management of brainstem gliomas in adults. A retrospective Italian study. J Neurol. 2008;255(2):171-7.
Reyes-Botero G, Mokhtari K, Martin-Duverneuil N, Delattre JY, Laigle-Donadey F. Adult brainstem gliomas. Oncologist. 2012;17(3):388-97.
Broniscer A, Laningham FH, Kocak M. Intratumoral hemorrhage among children with newly diagnosed, diffuse brainstem glioma. Cancer. 2006;106(6):1364-71.
Theeler BJ, Ellezam B, Melguizo-Gavilanes I, de Groot JF, Mahajan A, Aldape KD et al. Adult brainstem gliomas: correlation of clinical and molecular features. J Neurol Sci. 2015;353(1-2):92-7.
Bartels U, Hawkins C, Vézina G, Kun L, Souweidane M, Bouffet E. Proceedings of the diffuse intrinsic pontine glioma (DIPG) Toronto Think Tank: advancing basic and translational research and cooperation in DIPG. J Neurooncol. 2011;105(1):119-25.
Dellaretti M, Reyns N, Touzet G, Dubois F, Gusmão S, Pereira JL et al. Diffuse Brainstem Glioma: Prognostic Factors. J Neurosurg. 2012;117:810-4.
Hargrave D, Bartels U, Bouffet E. Diffuse Brainstem Glioma in Children: Critical Review of Clinical Trials. Lancet Oncol. 2006;7:241-8.
Laigle-Donadey F, Doz F, Delattre JY. Brainstem Gliomas in Children and Adults. Curr Opin Oncol. 2008;20:662-7.
Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C et al. Cbtrus Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro-Oncology. 2019;21:v1-v100.
Smith MA, Freidlin B, Ries LA, Simon R. Trends in Reported Incidence of Primary Malignant Brain Tumors in Children in the United States. J Natl Cancer Inst. 1998;90:1269-77.
Deland K, Starr BF, Mercer JS, Byemerwa J, Crabtree DM, Williams NT et al. Tumor Genotype Dictates Radiosensitization After Atm Deletion in Primary Brainstem Glioma Models. J Clin Invest. 2021;131(1):e142158.
Dellaretti M, Touzet G, Reyns N, Dubois F, Gusmao S, Pereira JL, Blond S. Correlation between magnetic resonance imaging findings and histological diagnosis of intrinsic brainstem lesions in adults. Neuro Oncol. 2012;14:381-5.
Massager N, David P, Goldman S, Pirotte B, Wikler D, Salmon I et al. Combined magnetic resonsace imaging- and positron emission tomography-guided stereotactic biopsy in brainstem mass lesions: diagnostic yield in a series of 30 patients. J Neurosurg. 2000;93:951-7.
Torcuator R, Zuniga R, Loutfi R, Mikkelsen T: Bevacizumab and irinotecan treatment for progressive diffuse brain stem glioma: case report. J Neurooncol. 2009;93:409-12.
Raza S, Donach M. Bevacizumab in adult malignant brainstem gliomas. J Neurooncol. 2009;95:299-300.
Reithmeier T, Lopez WO, Spehl TS, Nguyen T, Mader I, Nikkhah G et al. Bevacizumab as salvage therapy for progressive brain stem gliomas. Clin Neurol Neurosurg. 2013;115:165-9.
